About
From research to Startup
Navari is a MedTech startup based in Gothenburg, Sweden, on a mission to transform minimally invasive cancer surgery through advanced visualization technology, making the shift away from open surgery a reality.
The company began as an innovative research collaboration between Chalmers University of Technology and Sahlgrenska University Hospital. What started as a multidisciplinary project quickly gained traction, and after early validation, the concept was brought to Chalmers School of Entrepreneurship, where Navari’s future CEO and COO joined the effort.
Driven by their vision and commitment, Navari was officially founded in June 2021. Today, the team is focused on developing its first product, targeting liver cancer surgery as the initial step toward reshaping how cancer is treated worldwide.
Originating from clinical need
Navari’s story began with Dr. Niclas Kvarnström, MD/PhD, and the challenges he faced every day performing minimally invasive liver surgeries. Locating and removing cancer tumors with limited visibility made these procedures exceptionally complex, and highlighted a major barrier to wider adoption of minimally invasive techniques.
Recognizing this gap, Dr. Kvarnström teamed up with Professor Mårten Falkenberg to explore potential solutions. They quickly discovered that no suitable tools existed to meet the need. This realization sparked the idea for an augmented reality (AR) solution that could transform how surgeons see and operate.
To bring the concept to life, they collaborated with mathematics experts Prof. Klas Modin and Prof. Torbjörn Lundh, laying the scientific foundation for what would become Navari.
Current status
2022
Patent filed
In 2022, Navari filed its first patent for the completely novel single-use device. SInce then, two additional patents have been filed in 2024 and 2025.
2022
Pre-seed
2023
PoC in vivo achieved
In September 2023, Navari successfully conducted a preclinical study, validating the technology and achieving Proof of Concept in vivo.
